ArticleArthritis research & therapy2014
Targeting of viral interleukin-10 with an antibody fragment specific to damaged arthritic cartilage improves its therapeutic potency.
Article in Arthritis research & therapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 37 citations in OpenAlex.
- Evaluation of Serum and Urine Biomarker Panels for Developmental Dysplasia of the Hip Prior to Onset of Secondary Osteoarthritis.Cartilage · 2024Article
- Programmed Death Ligand 1-Expressing Macrophages and Their Protective Role in the Joint During Arthritis.Arthritis & rheumatology (Hoboken, N.J.) · 2024Article
- Immunomodulatory Microparticles Epigenetically Modulate T Cells and Systemically Ameliorate Autoimmune Arthritis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Pre-clinical development and molecular characterization of an engineered type 1 regulatory T-cell product suitable for immunotherapy.Cytotherapy · 2021Article
- Engineered Cytokines for Cancer and Autoimmune Disease Immunotherapy.Advanced healthcare materials · 2021Review
- Targeting Cartilage Degradation in Osteoarthritis.Pharmaceuticals (Basel, Switzerland) · 2021Review
- The Role and Impact of Extracellular Vesicles in the Modulation and Delivery of Cytokines during Autoimmunity.International journal of molecular sciences · 2020Review
- Molecular and structural imaging in surgically induced murine osteoarthritis.Osteoarthritis and cartilage · 2020Review
- Targeting Extracellular Vesicles to the Arthritic Joint Using a Damaged Cartilage-Specific Antibody.Frontiers in immunology · 2020Article
- Antibody-cytokine fusion proteins: A novel class of biopharmaceuticals for the therapy of cancer and of chronic inflammation.New biotechnology · 2019Review
- Evaluation of Targeting Efficiency of Joints with Anticollagen II Antibodies.Molecular pharmaceutics · 2019Article
- Targeting the extracellular matrix for delivery of bioactive molecules to sites of arthritis.British journal of pharmacology · 2019Review
- Molecular transport in articular cartilage - what have we learned from the past 50 years?Nature reviews. Rheumatology · 2018Review
- The interrelation of osteoarthritis and diabetes mellitus: considering the potential role of interleukin-10 and in vitro models for further analysis.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2018Review
- Evolution of the magic bullet: Single chain antibody fragments for the targeted delivery of immunomodulatory proteins.Experimental biology and medicine (Maywood, N.J.) · 2018Review
- Current progress in innovative engineered antibodies.Protein & cell · 2018Review
- Herpesviral capture of immunomodulatory host genes.Virus genes · 2017Review
- IL-10 ameliorates TNF-α induced meniscus degeneration in mature meniscal tissue in vitro.BMC musculoskeletal disorders · 2017Article
- Use of single chain antibody derivatives for targeted drug delivery.Molecular medicine (Cambridge, Mass.) · 2016Article
- Immunocytokines: a novel class of products for the treatment of chronic inflammation and autoimmune conditions.Drug discovery today · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
Abstract
introductionWe previously demonstrated that a single-chain fragment variable (scFv) specific to collagen type II (CII) posttranslationally modified by reactive oxygen species (ROS) can be used to target anti-inflammatory therapeutics specifically to inflamed arthritic joints. The objective of the present study was to demonstrate the superior efficacy of anti-inflammatory cytokines when targeted to inflamed arthritic joints by the anti-ROS modified CII (anti-ROS-CII) scFv in a mouse model of arthritis.
methodsViral interleukin-10 (vIL-10) was fused to anti-ROS-CII scFv (1-11E) with a matrix-metalloproteinase (MMP) cleavable linker to create 1-11E/vIL-10 fusion. Binding of 1-11E/vIL-10 to ROS-CII was determined by enzyme-linked immunosorbent assay (ELISA), Western blotting, and immune-staining of arthritic cartilage, whereas vIL-10 bioactivity was evaluated in vitro by using an MC-9 cell-proliferation assay. Specific in vivo localization and therapeutic efficacy of 1-11E/vIL-10 was tested in the mouse model of antigen-induced arthritis.
results1-11E/vIL-10 bound specifically to ROS-CII and to damaged arthritic cartilage. Interestingly, the in vitro vIL-10 activity in the fusion protein was observed only after cleavage with MMP-1. When systemically administered to arthritic mice, 1-11E/vIL-10 localized specifically to the arthritic knee, with peak accumulation observed after 3 days. Moreover, 1-11E/vIL-10 reduced inflammation significantly quicker than vIL-10 fused to the control anti-hen egg lysozyme scFv (C7/vIL10).
conclusionsTargeted delivery of anti-inflammatory cytokines potentiates their anti-arthritic action in a mouse model of arthritis. Our results further support the hypothesis that targeting biotherapeutics to arthritic joints may be extended to include anti-inflammatory cytokines that lack efficacy when administered systemically.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.